Expression and Role of Nuclear Receptor Coregulators in Colorectal Cancer Mouna Triki, Marion Lapierre, Vincent Cavaillès, Raja Mokdad-Gargouri

Total Page:16

File Type:pdf, Size:1020Kb

Expression and Role of Nuclear Receptor Coregulators in Colorectal Cancer Mouna Triki, Marion Lapierre, Vincent Cavaillès, Raja Mokdad-Gargouri Expression and role of nuclear receptor coregulators in colorectal cancer Mouna Triki, Marion Lapierre, Vincent Cavaillès, Raja Mokdad-Gargouri To cite this version: Mouna Triki, Marion Lapierre, Vincent Cavaillès, Raja Mokdad-Gargouri. Expression and role of nuclear receptor coregulators in colorectal cancer. World Journal of Gastroenterology, Baishideng Publishing Group Co. Limited, 2017, 23 (25), pp.4480 - 4490. 10.3748/wjg.v23.i25.4480. inserm- 02438832 HAL Id: inserm-02438832 https://www.hal.inserm.fr/inserm-02438832 Submitted on 14 Jan 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Submit a Manuscript: http://www.f6publishing.com World J Gastroenterol 2017 July 7; 23(25): 4480-4490 DOI: 10.3748/wjg.v23.i25.4480 ISSN 1007-9327 (print) ISSN 2219-2840 (online) REVIEW Expression and role of nuclear receptor coregulators in colorectal cancer Mouna Triki, Marion Lapierre, Vincent Cavailles, Raja Mokdad-Gargouri Mouna Triki, Marion Lapierre, Vincent Cavailles, IRCM, Peer-review started: August 3, 2016 Institut de Recherche en Cancérologie de Montpellier, INSERM First decision: September 5, 2016 U1194, Université de Montpellier, Institut régional du Cancer de Revised: September 30, 2016 Montpellier, 34298 Montpellier, France Accepted: October 31, 2016 Article in press: October 31, 2016 Mouna Triki, Raja Mokdad-Gargouri, Centre de Biotechnologie Published online: July 7, 2017 de Sfax, Université de Sfax, Sfax 3072, Tunisie Author contributions: Triki M performed the literature review and analysis, wrote the manuscript and contributed to the generation of figures; Lapierre M and Mokdad-Gargouri R Abstract contributed to the drafting, editing and critical revision of the Colorectal cancer (CRC) is one of the most common manuscript; Cavailles V designed the aim of the review, generated human cancers and the cause of about 700000 deaths the figures and wrote the manuscript; all authors approved the final version. per year worldwide. Deregulation of the WNT/β-catenin pathway is a key event in CRC initiation. This pathway Supported by SIRIC and the PHC-UTIQUE program, No. interacts with other nuclear signaling pathways, 16G 0805; PHC-UTIQUE program, No. 16G 0805; Tunisian including members of the nuclear receptor superfamily government (Bourse d’alternance); INSERM, Université de and their transcription coregulators. In this review, Montpellier, INCa, SIRIC Montpellier, the Institut régional du we provide an overview of the literature dealing with Cancer de Montpellier. the main coactivators (NCoA-1 to 3, NCoA-6, PGC1-α, p300, CREBBP and MED1) and corepressors (N-CoR1 Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported. and 2, NRIP1 and MTA1) of nuclear receptors and summarize their links with the WNT/β-catenin signaling Open-Access: This article is an open-access article which was cascade, their expression in CRC and their role in selected by an in-house editor and fully peer-reviewed by external intestinal physiopathology. reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, Key words: Immunohistochemistry; Colon cancer; which permits others to distribute, remix, adapt, build upon this Nuclear receptors; Transcription coregulators; WNT work non-commercially, and license their derivative works on signaling different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/ © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. Manuscript source: Unsolicited manuscript Core tip: Colorectal cancer (CRC) is one of the most Correspondence to: Vincent Cavaillès, PhD, IRCM, Institut common human cancers worldwide. Deregulation of the de Recherche en Cancérologie de Montpellier, INSERM U1194, WNT/β-catenin pathway is a key event in CRC initiation. Université de Montpellier, Institut régional du Cancer de This pathway interacts with other nuclear signaling Montpellier, 208 rue des apothicaires, 34298 Montpellier, pathways, including members of the nuclear receptor France. [email protected] Telephone: +33-4-67612405 superfamily and their transcription coregulators. In Fax: +33-4-67613787 this review, we provide an overview of the literature dealing with the main coactivators and corepressors of Received: August 2, 2016 nuclear receptors, and summarize their links with the WJG|www.wjgnet.com 4480 July 7, 2017|Volume 23|Issue 25| Triki M et al . Nuclear receptor coregulators in CRC WNT/β-catenin signaling cascade, their expression in in CRC[9]. In normal intestinal cells, WNT expression is CRC and their role in intestinal physiopathology. detected in cells at the crypt base and is essential for the maintenance of stem cell compartmentalization and, ultimately, for the intestinal tract organization and Triki M, Lapierre M, Cavailles V, Mokdad-Gargouri R. patterning. The WNT canonical pathway is activated Expression and role of nuclear receptor coregulators in colorectal upon binding of the WNT ligands to the Frizzled/ cancer. World J Gastroenterol 2017; 23(25): 4480-4490 LRP receptor. This interaction induces a signaling Available from: URL: http://www.wjgnet.com/1007-9327/full/ cascade, leading to the stabilization of β­catenin v23/i25/4480.htm DOI: http://dx.doi.org/10.3748/wjg.v23. in the cytoplasm and to its translocation into the i25.4480 nucleus. There, β­catenin interacts with the TCF/LEF transcription factors to modulate specific target genes that are involved in cell proliferation and differentiation, INTRODUCTION such as MYC, which encodes the Myc proto­oncogene, and CCND1, which encodes the cyclin D1 protein. In Colorectal cancer the absence of WNT ligands, β­catenin is targeted for Colorectal cancer (CRC) is the third most common proteasomal degradation upon phosphorylation through human cancer with more than 1.3 million recorded its association with a destruction complex composed cases in 2012. Patients are generally treated with of various scaffold proteins, such as adenomatous surgery, chemotherapy and radiotherapy that are polyposis coli (APC), Axin 2, glycogen synthase kinase associated with several side effects. Despite important 3 (GSK3) and casein kinase 1 (CK1). Approximately advances in CRC prognosis, diagnosis and treatment 70%­80% of sporadic CRCs involve somatic mutations during the last decade, it remains the cause of about that inactivate APC, leading to β­catenin accumulation [1] 700000 deaths per year worldwide . Although CRC and activation of its target genes. can be sporadic or hereditary, in both cases, environ­ mental factors contribute to its development. The main Nuclear receptor signaling risk factor is age; however, diet, sedentary lifestyle and Nuclear receptors (NRs) are ligand­activated trans­ tobacco smoking also increase the risk of developing cription factors that directly regulate genes and are [2] CRC . involved in several physiological processes, such as CRCs are complex and heterogeneous epithelial growth, homeostasis, differentiation, development tumors that involve various genetic and epigenetic and metabolism[10]. NR signaling dysregulation contri­ alterations. The progressive accumulation of these butes to various human diseases, including cancer[11]. molecular changes contributes to the transformation Currently, NRs represent one of the largest families of [3] of normal mucosa into neoplasia . At least three transcription factors (48 members in humans) that can molecular pathways have been identified as involved be classified in three groups (hormone, metabolic and [4] in CRC pathogenesis . The most common is the orphan NRs), based on their ligand properties[10,12]. chromosomal instability (CIN) pathway, characterized Members of the hormone receptor subfamily generally by inactivation of tumor suppressor genes (APC, bind to DNA as homodimers and include estrogen [5] TP53, SMAD4) and activation of oncogenes (KRAS) . (ERα and ERβ), androgen (AR), progesterone (PR), The hallmark of the second molecular pathway is glucocorticoid (GR) and mineralocorticoid receptors microsatellite instability (MSI) that results from the (MR). Metabolic receptors, such as farnesoid X (FXR), deregulation of DNA mismatch repair (MMR) genes, liver X (LXR) and peroxisome proliferator­activated [6] leading to genetic hypermutability . Finally, the third receptors (PPARs), bind to DNA as heterodimers molecular mechanism involves gene silencing via with their obligate partner retinoid X receptor (RXR). aberrant hypermethylation of promoter CpG islands Orphan receptors include all NRs for which ligands [7] (CpG island methylator phenotype, or CIMP) . A recent were (or are still) unknown[10]. NRs share a modular study has proposed a unique molecular classification structure composed of an N­terminal activation of CRC based on gene expression with four consensus domain, which is important for interactions with core­ molecular subtypes (CMS): MSI immune (CMS1), gulators (activators and
Recommended publications
  • Investigation of RIP140 and Lcor As Independent Markers for Poor Prognosis in Cervical Cancer
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 62), pp: 105356-105371 Research Paper Investigation of RIP140 and LCoR as independent markers for poor prognosis in cervical cancer Aurelia Vattai1, Vincent Cavailles2, Sophie Sixou3, Susanne Beyer1, Christina Kuhn1, Mina Peryanova1, Helene Heidegger1, Kerstin Hermelink1, Doris Mayr4, Sven Mahner1, Christian Dannecker1, Udo Jeschke1 and Bernd Kost1 1Department of Gynaecology and Obstetrics, Ludwig-Maximilians University of Munich, 80337 Munich, Germany 2Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université Montpellier, F-34298 Montpellier, France 3Université Toulouse III - Paul Sabatier, F-31062 Toulouse, France 4Department of Pathology, Ludwig-Maximilians University of Munich, 81337 Munich, Germany Correspondence to: Udo Jeschke, email: [email protected] Keywords: cervical carcinoma; squamous cell carcinoma; adenocarcinoma; RIP140/NRIP1; LCoR Received: May 18, 2017 Accepted: July 25, 2017 Published: October 31, 2017 Copyright: Vattai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Introduction: RIP140 (Receptor Interacting Protein) is involved in the regulation of oncogenic signaling pathways and in the development of breast and colon cancers. The aim of the study was to analyze the expression of RIP140 and its partner LCoR in cervical cancers, to decipher their relationship with histone protein modifications and to identify a potential link with patient survival. Methods: Immunohistochemical analyses were carried out to quantify RIP140 and LCoR expression in formalin-fixed paraffin-embedded tissue sections cervical cancer samples.
    [Show full text]
  • Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases
    Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Olivares, Ana Maria, Oscar Andrés Moreno-Ramos, and Neena B. Haider. 2015. “Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases.” Journal of Experimental Neuroscience 9 (Suppl 2): 93-121. doi:10.4137/JEN.S25480. http:// dx.doi.org/10.4137/JEN.S25480. Published Version doi:10.4137/JEN.S25480 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:27320246 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Journal name: Journal of Experimental Neuroscience Journal type: Review Year: 2015 Volume: 9(S2) Role of Nuclear Receptors in Central Nervous System Running head verso: Olivares et al Development and Associated Diseases Running head recto: Nuclear receptors development and associated diseases Supplementary Issue: Molecular and Cellular Mechanisms of Neurodegeneration Ana Maria Olivares1, Oscar Andrés Moreno-Ramos2 and Neena B. Haider1 1Department of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA. 2Departamento de Ciencias Biológicas, Facultad de Ciencias, Universidad de los Andes, Bogotá, Colombia. ABSTRACT: The nuclear hormone receptor (NHR) superfamily is composed of a wide range of receptors involved in a myriad of important biological processes, including development, growth, metabolism, and maintenance.
    [Show full text]
  • Multiple Functions and Essential Roles of Nuclear Receptor Coactivators of Bhlh-PAS Family
    This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/ licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ENDOCRINE REGULATIONS, Vol. 50, No. 3, 165–181, 2016 165 doi:10.1515/enr-2016-0019 Multiple functions and essential roles of nuclear receptor coactivators of bHLH-PAS family Pecenova L, Farkas R Laboratory of Developmental Genetics, Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia E-mail: [email protected] Classical non-peptide hormones, such as steroids, retinoids, thyroid hormones, vitamin D3 and their derivatives including prostaglandins, benzoates, oxysterols, and bile acids, are collectively designated as small lipophilic ligands, acting via binding to the nuclear receptors (NRs). The NRs form a large superfamily of transcription factors that participate virtually in every key biological process. They control various aspects of animal development, fertility, gametogenesis, and numer- ous metabolic pathways, and can be misregulated in many types of cancers. Their enormous func- tional plasticity, as transcription factors, relates in part to NR-mediated interactions with plethora of coregulatory proteins upon ligand binding to their ligand binding domains (LBD), or following covalent modification. Here, we review some general views of a specific group of NR coregulators, so-called nuclear receptor coactivators (NRCs) or steroid receptor coactivators (SRCs) and high- light some of their unique functions/roles, which are less extensively mentioned and discussed in other reviews. We also try to pinpoint few neglected moments in the cooperative action of SRCs, which may also indicate their variable roles in the hormone-independent signaling pathways.
    [Show full text]
  • Identifying the Role of Wilms Tumor 1 Associated Protein in Cancer Prediction Using Integrative Genomic Analyses
    MOLECULAR MEDICINE REPORTS 14: 2823-2831, 2016 Identifying the role of Wilms tumor 1 associated protein in cancer prediction using integrative genomic analyses LI‑SHENG WU1*, JIA-YI QIAN2*, MINGHAI WANG3* and HAIWEI YANG4 1Department of General Surgery, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230001; 2Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029; 3Department of General Surgery, The First Affiliated Yijishan Hospital of Wannan Medical College, Wuhu, Anhui 241002; 4Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China Received August 31, 2015; Accepted June 2, 2016 DOI: 10.3892/mmr.2016.5528 Abstract. The Wilms tumor suppressor, WT1 was first iden- regulatory factor 1, glucocorticoid receptor and peroxisome tified due to its essential role in the normal development of proliferator‑activated receptor γ transcription factor binding the human genitourinary system. Wilms tumor 1 associated sites were identified in the upstream (promoter) region of the protein (WTAP) was subsequently revealed to interact with human WTAP gene, suggesting that these transcription factors WT1 using yeast two‑hybrid screening. The present study may be involved in WTAP functions in tumor formation. identified 44 complete WTAP genes in the genomes of verte- brates, including fish, amphibians, birds and mammals. The Introduction vertebrate WTAP proteins clustered into the primate, rodent and teleost lineages using phylogenetic tree analysis. From The Wilms tumor suppressor gene WT1 was first identified 1,347 available SNPs in the human WTAP gene, 19 were due to its essential role in the normal development of the identified to cause missense mutations.
    [Show full text]
  • PALI1 Facilitates DNA and Nucleosome Binding by PRC2 and Triggers an Allosteric Activation of Catalysis
    ARTICLE https://doi.org/10.1038/s41467-021-24866-3 OPEN PALI1 facilitates DNA and nucleosome binding by PRC2 and triggers an allosteric activation of catalysis Qi Zhang1,3, Samuel C. Agius1,3, Sarena F. Flanigan1, Michael Uckelmann1, Vitalina Levina1, Brady M. Owen1 & ✉ Chen Davidovich 1,2 1234567890():,; The polycomb repressive complex 2 (PRC2) is a histone methyltransferase that maintains cell identities. JARID2 is the only accessory subunit of PRC2 that known to trigger an allosteric activation of methyltransferase. Yet, this mechanism cannot be generalised to all PRC2 variants as, in vertebrates, JARID2 is mutually exclusive with most of the accessory subunits of PRC2. Here we provide functional and structural evidence that the vertebrate- specific PRC2 accessory subunit PALI1 emerged through a convergent evolution to mimic JARID2 at the molecular level. Mechanistically, PRC2 methylates PALI1 K1241, which then binds to the PRC2-regulatory subunit EED to allosterically activate PRC2. PALI1 K1241 is methylated in mouse and human cell lines and is essential for PALI1-induced allosteric activation of PRC2. High-resolution crystal structures revealed that PALI1 mimics the reg- ulatory interactions formed between JARID2 and EED. Independently, PALI1 also facilitates DNA and nucleosome binding by PRC2. In acute myelogenous leukemia cells, overexpression of PALI1 leads to cell differentiation, with the phenotype altered by a separation-of-function PALI1 mutation, defective in allosteric activation and active in DNA binding. Collectively, we show that PALI1 facilitates catalysis and substrate binding by PRC2 and provide evidence that subunit-induced allosteric activation is a general property of holo-PRC2 complexes. 1 Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC, Australia.
    [Show full text]
  • Nuclear Receptor Assay Applications Presented Fall 2009
    Nuclear Receptor Assay Applications Presented Fall 2009 Click the icon in the upper left hand corner to view speaker notes for slides. Have a question? Ask a Scientist GloResponse is a trademark and Dual-Luciferase is a registered trademark of Promega Corporation. HighWire Press is a registered trademark of the Board of Trustees of the Leland Stanford Junior University ©2009, Promega Corporation. All rights reserved. Application Overview POST-TRANSCRIPTION MIRNA CONTROL In vivo PROTEIN applications INTERACTIONS expression level varies with treatment NUCLEAR RECEPTORS SIGNALING Experimental firefly luciferase PATHWAY construct expression level varies little with PROMOTER treatment Control DISSECTION Renilla luciferase construct 2 Traditional Nuclear Receptor Assays Steroid A good assay Works with endogenous receptors Steroid Receptor RNA Pol II NRE luciferase 3 Your expression analysis found an uncharacterized NR… N-Terminal Hinge C-Terminal Domain Region Domain A/B C D E F DNA Binding Ligand Binding Domain Domain •Response elements are not specifically known •Agonists are not known •Coactivators are not known •How can you do work on this nuclear receptor? A One-Hybrid Luciferase Reporter Assay can help understand the nuclear receptor more fully 4 Universal Nuclear Receptor Assays Ligand binding domain responsible for: • homodimerization (class I receptors) • heterodimerization (class II receptors) • corepressor binding • coactivator binding Nuclear Receptor Ligand Binding Domain pBIND Vector GAL4 BD GAL4 GAL4 GAL4 GAL4 GAL4 GAL4 GAL4
    [Show full text]
  • Understanding Nuclear Receptor Form and Function Using Structural Biology
    F RASTINEJAD and others Understanding NR form 51:3 T1–T21 Thematic Review and function Understanding nuclear receptor form and function using structural biology Correspondence Fraydoon Rastinejad, Pengxiang Huang, Vikas Chandra and Sepideh Khorasanizadeh should be addressed to F Rastinejad Metabolic Signaling and Disease Program, Sanford-Burnham Medical Research Institute, Orlando, Email Florida 32827, USA frastinejad@ sanfordburnham.org Abstract Nuclear receptors (NRs) are a major transcription factor family whose members selectively Key Words bind small-molecule lipophilic ligands and transduce those signals into specific changes in " nuclear receptors gene programs. For over two decades, structural biology efforts were focused exclusively on " steroid hormones the individual ligand-binding domains (LBDs) or DNA-binding domains of NRs. These " transcription factors analyses revealed the basis for both ligand and DNA binding and also revealed receptor " gene regulation conformations representing both the activated and repressed states. Additionally, " metabolism crystallographic studies explained how NR LBD surfaces recognize discrete portions of transcriptional coregulators. The many structural snapshots of LBDs have also guided the development of synthetic ligands with therapeutic potential. Yet, the exclusive structural focus on isolated NR domains has made it difficult to conceptualize how all the NR polypeptide segments are coordinated physically and functionally in the context of receptor Journal of Molecular Endocrinology quaternary architectures. Newly emerged crystal structures of the peroxisome proliferator- activated receptor-g–retinoid X receptor a (PPARg–RXRa) heterodimer and hepatocyte nuclear factor (HNF)-4a homodimer have recently revealed the higher order organizations of these receptor complexes on DNA, as well as the complexity and uniqueness of their domain–domain interfaces.
    [Show full text]
  • Regulation of Lcor and RIP140 Expression in Cervical Intraepithelial Neoplasia and Correlation with CIN Progression and Dediffer
    Journal of Cancer Research and Clinical Oncology (2020) 146:1847–1855 https://doi.org/10.1007/s00432-020-03178-x ORIGINAL ARTICLE – CLINICAL ONCOLOGY Regulation of LCoR and RIP140 expression in cervical intraepithelial neoplasia and correlation with CIN progression and dediferentiation Tilman L. R. Vogelsang1 · Elisa Schmoeckel3 · Christina Kuhn1 · Thomas Blankenstein1 · Mina Temelkov1 · Helene Heidegger1 · Theresa Maria Kolben1 · Thomas Kolben1 · Sven Mahner1 · Doris Mayr3 · Udo Jeschke1,2 · Aurelia Vattai1 Received: 10 February 2020 / Accepted: 3 March 2020 / Published online: 10 March 2020 © The Author(s) 2020 Abstract Purpose Ligand-dependent corepressor (LCoR) and receptor-interacting protein 140 (RIP140/NRIP1) play an important role in the regulation of multiple oncogenic signaling pathways and the development of cancer. LCoR and RIP140 form a nuclear complex in breast cancer cells and are of prognostic value in further prostate and cervical cancer. The purpose of this study was to analyze the regulation of these proteins in the development of cervical intraepithelial neoplasia (CIN I–III). Methods Immunohistochemical analysis was obtained to quantify RIP140 and LCoR expression in formalin-fxed parafn embedded tissue sections of cervical intraepithelial neoplasia samples. Tissue (n = 94) was collected from patients treated in the Department of Gynecology and Obstetrics, Ludwig-Maximilians-University of Munich, Germany, between 2002 and 2014. Correlations of expression levels with clinical outcome were carried out to assess for prognostic relevance in patients with CIN2 progression. Kruskal–Wallis test and Mann–Whitney U test were used for data analysis. Results Nuclear LCoR overexpression correlates signifcantly with CIN II progression. Nuclear RIP140 expression signif- cantly increases and nuclear LCoR expression decreases with higher grading of cervical intraepithelial neoplasia.
    [Show full text]
  • HER2 Gene Signatures: (I) Novel and (Ii) Established by Desmedt Et Al 2008 (31)
    Table S1: HER2 gene signatures: (i) Novel and (ii) Established by Desmedt et al 2008 (31). Pearson R [neratinib] is the correlation with neratinib response using a pharmacogenomic model of breast cancer cell lines (accessed online via CellMinerCDB). *indicates significantly correlated genes. n/a = data not available in CellMinerCDB Genesig N Gene ID Pearson R [neratinib] p-value (i) Novel 20 ERBB2 0.77 1.90E-08* SPDEF 0.45 4.20E-03* TFAP2B 0.2 0.24 CD24 0.38 0.019* SERHL2 0.41 0.0097* CNTNAP2 0.12 0.47 RPL19 0.29 0.073 CAPN13 0.51 1.00E-03* RPL23 0.22 0.18 LRRC26 n/a n/a PRODH 0.42 9.00E-03* GPRC5C 0.44 0.0056* GGCT 0.38 1.90E-02* CLCA2 0.31 5.70E-02 KDM5B 0.33 4.20E-02* SPP1 -0.25 1.30E-01 PHLDA1 -0.54 5.30E-04* C15orf48 0.06 7.10E-01 SUSD3 -0.09 5.90E-01 SERPINA1 0.14 4.10E-01 (ii) Established 24 ERBB2 0.77 1.90E-08* PERLD1 0.77 1.20E-08* PSMD3 0.33 0.04* PNMT 0.33 4.20E-02* GSDML 0.4 1.40E-02* CASC3 0.26 0.11 LASP1 0.32 0.049* WIPF2 0.27 9.70E-02 EPN3 0.42 8.50E-03* PHB 0.38 0.019* CLCA2 0.31 5.70E-02 ORMDL2 0.06 0.74 RAP1GAP 0.53 0.00059* CUEDC1 0.09 0.61 HOXC11 0.2 0.23 CYP2J2 0.45 0.0044* HGD 0.14 0.39 ABCA12 0.07 0.67 ATP2C2 0.42 0.0096* ITGA3 0 0.98 CEACAM5 0.4 0.012* TMEM16K 0.15 0.37 NR1D1 n/a n/a SNX7 -0.28 0.092 FJX1 -0.26 0.12 KCTD9 -0.11 0.53 PCTK3 -0.04 0.83 CREG1 0.17 0.3 Table S2: Up-regulated genes from the top 500 DEGs for each comparison by WAD score METABRIC METABRIC METABRIC TCGA ERBB2amp ERBB2mut oncERBB2mut HER2+ ERBB2 PIP ANKRD30A ERBB2 GRB7 CYP4Z1 CYP4Z1 SCGB2A2 PGAP3 PROM1 LRRC26 SPDEF GSDMB CD24 PPP1R1B FOXA1
    [Show full text]
  • A Tumor Suppressive Coactivator Complex of P53 Containing ASC-2 and Histone H3-Lysine-4 Methyltransferase MLL3 Or Its Paralogue MLL4
    A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4 Jeongkyung Leea, Dae-Hwan Kima, Seunghee Leea, Qi-Heng Yangb, Dong Kee Leea, Soo-Kyung Leea, Robert G. Roederb,1, and Jae W. Leea,1 aDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030; and bLaboratory of Biochemistry and Molecular Biology, The Rockefeller University, 1230 York Avenue, New York, NY 10021 Contributed by Robert G. Roeder, March 14, 2009 (sent for review March 5, 2009) ASC-2, a multifunctional coactivator, forms a steady-state complex, To elucidate the physiological role of ASCOM, we recently named ASCOM (for ASC-2 COMplex), that contains the histone established a homozygous mouse line designated MLL3⌬/⌬ (8). H3-lysine-4 (H3K4)-methyltransferase MLL3 or its paralogue MLL4. In these mice, wild-type MLL3 is replaced by a mutant MLL3 Somewhat surprisingly, given prior indications of redundancy that contains an in-frame deletion of a 61-aa catalytic core between MLL3 and MLL4, targeted inactivation of the MLL3 H3K4- region in the MLL3 SET domain and that is expressed and methylation activity in mice is found to result in ureter epithelial incorporated into ASCOM (8). Unlike ASC-2-null mice, which tumors. Interestingly, this phenotype is exacerbated in a p53؉/؊ die at approximately E9.5-E13.5 (1), MLL3⌬/⌬ mice show only a background and the tumorigenic cells are heavily immunostained partial embryonic lethality (8). Interestingly, genetic data are for ␥H2AX, indicating a contribution of MLL3 to the DNA damage also indicative of interactions between MLL3 and ASC-2, be- response pathway through p53.
    [Show full text]
  • Supp Table 6.Pdf
    Supplementary Table 6. Processes associated to the 2037 SCL candidate target genes ID Symbol Entrez Gene Name Process NM_178114 AMIGO2 adhesion molecule with Ig-like domain 2 adhesion NM_033474 ARVCF armadillo repeat gene deletes in velocardiofacial syndrome adhesion NM_027060 BTBD9 BTB (POZ) domain containing 9 adhesion NM_001039149 CD226 CD226 molecule adhesion NM_010581 CD47 CD47 molecule adhesion NM_023370 CDH23 cadherin-like 23 adhesion NM_207298 CERCAM cerebral endothelial cell adhesion molecule adhesion NM_021719 CLDN15 claudin 15 adhesion NM_009902 CLDN3 claudin 3 adhesion NM_008779 CNTN3 contactin 3 (plasmacytoma associated) adhesion NM_015734 COL5A1 collagen, type V, alpha 1 adhesion NM_007803 CTTN cortactin adhesion NM_009142 CX3CL1 chemokine (C-X3-C motif) ligand 1 adhesion NM_031174 DSCAM Down syndrome cell adhesion molecule adhesion NM_145158 EMILIN2 elastin microfibril interfacer 2 adhesion NM_001081286 FAT1 FAT tumor suppressor homolog 1 (Drosophila) adhesion NM_001080814 FAT3 FAT tumor suppressor homolog 3 (Drosophila) adhesion NM_153795 FERMT3 fermitin family homolog 3 (Drosophila) adhesion NM_010494 ICAM2 intercellular adhesion molecule 2 adhesion NM_023892 ICAM4 (includes EG:3386) intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)adhesion NM_001001979 MEGF10 multiple EGF-like-domains 10 adhesion NM_172522 MEGF11 multiple EGF-like-domains 11 adhesion NM_010739 MUC13 mucin 13, cell surface associated adhesion NM_013610 NINJ1 ninjurin 1 adhesion NM_016718 NINJ2 ninjurin 2 adhesion NM_172932 NLGN3 neuroligin
    [Show full text]
  • REVIEW Agonist-Bound Nuclear Receptors: Not Just Targets of Coactivators
    1 REVIEW Agonist-bound nuclear receptors: not just targets of coactivators I Fernandes and J H White1 Department of Physiology, McGill University, McIntyre Medical Sciences Bldg., 3655 Drummond St, Montreal, Quebec H3G 1Y6, Canada 1Department of Medicine, McGill University, McIntyre Medical Sciences Bldg., 3655 Drummond St, Montreal, Quebec H3G 1Y6, Canada (Requests for offprints should be addressed to J H White; Email: [email protected]) Abstract Members of the nuclear receptor superfamily of ligand-regulated transcription factors are targets of a wide range of lipophilic signaling molecules as well as several drugs and xenobiotics that modulate many aspects of physiology and metabolism. Agonist binding to receptors is associated with recruitment of coactivators, which are essential for activation of target gene transcription. However, several biochemical and molecular genetic studies have shown that a full understanding of the function of agonist-bound receptors must also accommodate the recruitment of corepressors. These factors may attenuate agonist-induced transactivation, act more transiently as part of a cycle of cofactors recruited to target promoters by ligand-bound receptors, or function in hormone-dependent repression of target gene expression. Journal of Molecular Endocrinology (2003) 31, 1–7 The nuclear receptor superfamily – have broad potential as anticancer agents. To primary targets of lipophilic signaling understand the physiological and pharmacological molecules actions of specific ligands, it is essential to fully characterize the biochemical events induced by Nuclear receptors are ligand-regulated transcrip- their binding to target receptors. tion factors whose activities are controlled by a Nuclear receptors contain well-conserved DNA range of lipophilic extracellular signals, including binding domains (DBD) and ligand binding steroid and thyroid hormones, metabolites of domains (LBD).
    [Show full text]